Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination ; volume:21 ; number:1 ; day:21 ; month:3 ; year:2024 ; pages:1-7 ; date:12.2024
Virology journal ; 21, Heft 1 (21.3.2024), 1-7, 12.2024
- Urheber
-
Cheng, Samuel M.S
Mok, Chris K.P
Li, John K.C
Chan, Ken K.P
Luk, Kristine S.
Lee, Ben H.W
Gu, Haogao
Chan, Karl C.K
Tsang, Leo C.H
Yiu, Karen Y.S
Ling, Ken K.C
Tang, Yun Sang
Luk, Leo L.H
Yu, Jennifer K.M
Pekosz, Andrew
Webby, Richard J.
Cowling, Benjamin J.
Hui, David S.C
Peiris, Malik
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12985-024-02335-9
- URN
-
urn:nbn:de:101:1-2405230724591.266968515054
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cheng, Samuel M.S
- Mok, Chris K.P
- Li, John K.C
- Chan, Ken K.P
- Luk, Kristine S.
- Lee, Ben H.W
- Gu, Haogao
- Chan, Karl C.K
- Tsang, Leo C.H
- Yiu, Karen Y.S
- Ling, Ken K.C
- Tang, Yun Sang
- Luk, Leo L.H
- Yu, Jennifer K.M
- Pekosz, Andrew
- Webby, Richard J.
- Cowling, Benjamin J.
- Hui, David S.C
- Peiris, Malik
- SpringerLink (Online service)
Ähnliche Objekte (12)
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease